Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments

This is a dose escalation study. As subjects participating in the study tolerate a specific dose level, the new subjects entering will be given a higher dose of the study drug.

Inclusion criteria

• recurrent cancer refractory to available systemic therapy
• 18 years old or older
• predicted life expectancy equal or greater to 8 weeks
• at least 4 weeks post chemotherapy, immunotherapy, surgery, or radiation therapy and have recovered from treatment toxicities
• Karnofsky Performance Status equal or greater to 60 or ECOG equal or less than 2
• adequate organ function based on hematological, liver, and renal function
• LVEF greater than the lower limit of normal for the institution, as measured by MUGA or by echocardiography
• wash-out period before first dose os study drug if a protocol prohibited medication is being discontinued

Exclusion criteria

• pregnant or breastfeeding
• received any other anti-cancer treatment or investigational therapy within 28 days prior to Cycle 1 Day 1
• symptoms of heart failure equal or greater to Class III (by NYHA criteria)
• impaired cardiac function or clinically significant cardiac diseases
• concurrent treatment with medications that either markedly induce or inhibit CYP3A4
• concurrent treatment with medications that have a relative risk of prolonging the QT interval or inducing torsades de pointes if treatment cannot be discontinued or switched to a different medication prior to study drug